Factors associated with long-term efficacy of lubiprostone for chronic constipation
-
- Morise Takashi
- Department of Gastroenterology and Hepatology, Tokyo Medical University Hospital
-
- Fukuzawa Masakatsu
- Department of Gastroenterology and Hepatology, Tokyo Medical University Hospital
-
- Sugimoto Mitsushige
- Endoscopy Center, Tokyo Medical University Hospital
-
- Nagata Naoyoshi
- Endoscopy Center, Tokyo Medical University Hospital
-
- Kono Shin
- Department of Gastroenterology and Hepatology, Tokyo Medical University Hospital
-
- Yamauchi Yoshiya
- Department of Gastroenterology and Hepatology, Tokyo Medical University Hospital
-
- Sugimoto Akihiko
- Department of Gastroenterology and Hepatology, Tokyo Medical University Hospital
-
- Uchida Kumiko
- Department of Gastroenterology and Hepatology, Tokyo Medical University Hospital
-
- Koyama Yohei
- Department of Gastroenterology and Hepatology, Tokyo Medical University Hospital
-
- Madarame Akira
- Department of Gastroenterology and Hepatology, Tokyo Medical University Hospital
-
- Yamaguchi Hayato
- Department of Gastroenterology and Hepatology, Tokyo Medical University Hospital
-
- Matsumoto Taisuke
- Department of Gastroenterology and Hepatology, Tokyo Medical University Hospital
-
- Kagawa Yasuyuki
- Department of Gastroenterology and Hepatology, Tokyo Medical University Hospital
-
- Kawai Takashi
- Endoscopy Center, Tokyo Medical University Hospital
-
- Itoi Takao
- Department of Gastroenterology and Hepatology, Tokyo Medical University Hospital
抄録
<p>The prevalence of chronic constipation in Japan is increasing, and is presently almost 1 in 5 people. Because constipation is common, especially in older patients, to avoid adverse events and polypharmacy, simple treatments at low doses are generally desired. Although the chloride channel activator lubiprostone is candidate drug that may solve these problems, factors associated with the long-term efficacy of lubiprostone monotherapy for chronic constipation in treatment-naive patients remain unclear. We here retrospectively investigated the clinical characteristics and factors of patients who achieved long-term constipation improvement with lubiprostone monotherapy. Seventy-four patients with chronic constipation treated with lubiprostone monotherapy (24 or 48 μg/day) from January 2017 to August 2018 were reviewed. Patient characteristics and clinical time-courses were compared between those who sustained improvement for 6 months, and those who became refractory to treatment. In 54 patients (76.1%), constipation improved by lubiprostone administration for 6 months. On multivariate analysis, a significant clinical factor associated with sustained improvement was a starting lubiprostone dose of 24 μg/day (odds ratio: 5.791; 95% confidence interval: 1.032–32.498; p = 0.046). A starting lubiprostone dose of 24 μg/day has efficacy to improve chronic constipation and to prevent adverse events of nausea and diarrhea in Japanese patients.</p>
収録刊行物
-
- Ｊｏｕｒｎａｌ ｏｆ Ｃｌｉｎｉｃａｌ Ｂｉｏｃｈｅｍｉｓｔｒｙ ａｎｄ Ｎｕｔｒｉｔｉｏｎ
-
Ｊｏｕｒｎａｌ ｏｆ Ｃｌｉｎｉｃａｌ Ｂｉｏｃｈｅｍｉｓｔｒｙ ａｎｄ Ｎｕｔｒｉｔｉｏｎ 73 (1), 91-96, 2023
一般社団法人 日本酸化ストレス学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390859616464002816
-
- ISSN
- 18805086
- 09120009
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
-
- 抄録ライセンスフラグ
- 使用不可